MAPT and Alzheimer disease: Besides, as one of the current therapeutic approaches to tauopathies is to find highly specific inhibitors to prevent tau pathological phase transition [37], our continuing work is relatedly focused on developing an AD cell model based on the 2N-tau-EGFP HT22 to undergo a high-throughput screening to identify small-molecule compounds that could restore the normal behavior of tau condensates [38].